



**PREVECEUTICAL**<sup>®</sup>  
PREVENTIVE HEALTH SCIENCES

# CORPORATE PRESENTATION

**January 2025**

CSE: PREV  
OTCQB: PRVCF  
FSE: 18H



# DISCLAIMER

This presentation and its appendices (together the "Presentation") have been prepared and delivered by PreveCeutical® Medical Inc. ("PreveCeutical" or the "Company") (CSE: PREV, OTCQB: PRVCF, FSE: 18H). The Presentation and its contents are strictly confidential and may not be reproduced or redistributed, in whole or in part, to any other person than the intended recipient without the Company's written consent.

The Presentation is prepared for discussion and informational purposes only. The Presentation does not constitute, and should not be construed as, any offer or invitation or recommendation to buy or sell any of the securities issued by the Company and does and will not constitute or form or be part of any offering material. This Presentation is not meant for and should not be distributed to U.S. Persons (as defined in Regulation S of the United States Securities Act of 1933, as amended) or otherwise distributed in the United States of America.

The Presentation contains information which has been sourced from third parties believed to be reliable, but without independent verification by the Company, its board of directors, management, employees, consultants, agents, or affiliates. The Presentation contains certain forward-looking statements relating to the potential business, financial performance and results of the Company and/or industries and markets in which it is or may operate within, including forward-looking forecasts. These statements may contain words such as "will", "expects", "anticipates", "believes", "estimates" and words of similar import. Any forward-looking statements and other information contained in this Presentation, including assumptions, opinions, forecasts and views, including those cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. As such by the nature of any forward-looking statement, relying on such statements involves risk.

This Presentation has not been reviewed or registered with any public authority, stock exchange or regulated market-place.

By attending/reviewing/reading or receiving this Presentation you acknowledge that you will be solely responsible for your own assessment of the information herein, and the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company or any potential future investment in the Company. Neither the Company, its management or board of directors, nor any subsidiary of the Company or any such person's board of directors, management or affiliates makes any undertaking, representation or warranty (express or implied) as to the accuracy or completeness of the information (whether written or oral and whether or not included in this Presentation including related to any materials referred to or otherwise incorporated by reference herein) concerning the matters described herein. Neither the Company nor any subsidiary of the Company or any such person's board of directors, management, employees, consultants, agents, or affiliates accepts any liability whatsoever as to any errors, omissions or misstatements contained herein and, accordingly, neither the Company nor any subsidiary of the Company or any such person's affiliates, agents, officers, directors, employees, and consultants accepts any liability whatsoever arising directly or indirectly from the use of this Presentation or the information included herein.

The Presentation speaks and reflects prevailing conditions and views as of the date denoted on the cover page. It may be subject to corrections and change at any time without notice. Neither the Company nor any subsidiary of the Company or any such person's board of directors, management, employees, consultants, agents, or affiliates intends to, and neither the delivery of this Presentation nor any further discussions with any recipient shall, under any circumstances, create any implication that the Company or any of the aforementioned parties assumes any obligation to update or correct the information herein unless required by applicable law. The information in this Presentation is current as of the date of this Presentation noted on its first page, and readers are encouraged to review the Company's public filings on its SEDAR profile on [www.sedar.com](http://www.sedar.com).

# CORPORATE OVERVIEW

Preventive health sciences company with corporate offices in Vancouver, Canada, and wholly owned subsidiary in Brisbane, Australia.

Leveraging innovative science & technology to enhance natural products as novel targeted therapeutics in a diverse portfolio of R&D programs addressing significant life-affecting diseases.

Focus on developing Nature Identical® products and therapies for health-conscious consumers and becoming a trusted provider of preventive health solutions globally.

Building an extensive library of intellectual properties to enter into JV, development and licensing agreements with leaders in pharmaceutical and cannabis industries.



# PIPELINE OVERVIEW

MEETING UNMET CLINICAL NEEDS

01.

## Non-Addictive Analgesic

Non-Addictive Analgesic Peptides for Pain Management

Developing highly biostable peptides to substitute dependence-associated opioids such as morphine, fentanyl and oxycodone.

02.

## Cannabinoid Sol-Gel Delivery

Nose-to-Brain Delivery of Therapeutic Cannabinoids

Water soluble, patient safe, cannabinoid formulations for the clinical relief of a range of indications from pain to neurological disorders.

03.

## BSV Peptide Program

Targeting Cancer Progression

Developing highly biostable peptides aiming to treat, regulate & prevent cancer progression.

PreveCeutical® can employ the Linker Technology, a proprietary one-step synthesis that prevents degradation. Resulting in a Nature Identical™ product that can effectively be manufactured as the market demands.

# MARKET

## Cannabinoid Sol-Gel Delivery

**\$116.2 Billion**  
in 2020

CNS Therapeutic Market

**\$140.5 Billion**  
in 2030

Global Chronic Pain Market

## BSV Peptide Program

**\$365.99 Billion**  
by 2030

Global Market for  
Cancer Treatments

**\$106.0 Billion**  
by 2030

Global peptide therapeutics  
market is expected to reach

## Non-Addictive Analgesic

**\$1.5 Trillion**  
in 2020

Opioid crisis cost the  
U.S.A. nearly

**\$149.3 Billion**  
by 2030

Analgesics Market expected  
to hit

# NON-ADDICTIVE ANALGESIC

NON-ADDICTIVE ANALGESIC (DYNORPHIN PAIN PEPTIDE)

**Developing highly biostable peptides for the relief of 'moderate-to-severe', nociceptive, acute & chronic pain to substitute dependence-associated opioids such as morphine, fentanyl and oxycodone**

Highly potent and stable for extended periods in biological fluids and are purported to avoid addictive and tolerance-inducing side effects.

Demonstrated potency, in a well-accepted functional dose response assay, that is on par with clinically available agents such as morphine.

The research program commenced mid-2018, and is being led by PreveCeutical's Chief Research Officer, Dr. Harendra Parekh, in collaboration with UQ School of Pharmacy's pain & inflammation pharmacology expert, Associate Professor Peter Cabot.

## NOTABLE

01.

Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases.

02.

PreveCeutical® intends for the Research Program to progress into preclinical evaluations of the lead, highly potent and stable peptide candidates in a well-established model of pain and inflammation.

# NON-ADDICTIVE ANALGESIC

USING THE BODY'S OWN ENDOGENOUS PATHWAYS

## Clinically Available Agents (such as "Morphine or Fentanyl")

Inherent development of tolerance, addiction, depression etc., to ALL clinically available agents for management of moderate-to-severe pain, primarily dictated by opioid receptor sub-types, the agents bind to, and nature of binding to mu, delta & kappa opioid receptors.

ALL clinically available agents to treat moderate-to-severe pain target the mu-opioid receptor.

## Body's Endogenous Pain-Killing Peptides ("Dynorphin")

In response to pain and inflammation, the body releases pain-killing substances (antinociceptive peptides "Dynorphin") EACH time an injury occurs. The body does NOT develop addiction or tolerance to these pain killing peptides

Dynorphin preferentially 'bind' delta & kappa-opioid receptors. Dynorphin (1-7) contains all the necessary features for OP activation. Shows equal affinity for delta & kappa-opioid receptors



# NON-ADDICTIVE ANALGESIC

Two Australian provisional applications entitled, “A Cyclic Peptide”, which were filed last year by The University of Queensland, Australia (“UQ”) have recently been combined into a single PCT application.

This PCT application, jointly owned by UQ and PreveCeutical®, was filed on January 24, 2020, with application number PCT/AU2020/050049, with the aim of seeking protection for certain cyclic peptides and their use in pain management.



This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways... Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives."

**–Chief Research Officer,,  
Dr. Harry Parekh**



# CANNABINOID SOL-GEL DELIVERY

## NOSE-TO-BRAIN DELIVERY OF THERAPEUTIC CANNABINOIDS

Water soluble, patient safe, cannabinoid formulations for the clinical relief of a range of indications from pain to neurological disorders.

Developing, the first sustained-release, cannabinoid-based formulations for nose-to-brain delivery via a custom nasal spray device for ultra nasal drug delivery. An ideal vector for improving therapeutic outcomes for patients seeking access to cannabinoid-based products and therapies. Providing clinical relief across a range of indications from pain, inflammation, seizures and neurological disorders.

A novel process for preparing insoluble drug-containing Sol-gels has been developed by Preveceutical's Chief Research Officer, Dr. Harendra Parekh. The Cannabinoid Sol-gel formulations belong to PreveCeutical®.

### NOTABLE

01.

Bypasses first-pass metabolism in the stomach, intestines and liver, exhibiting a dramatic improvement in bioavailability, even when compared to conventional liquid nasal sprays and alternative delivery mechanisms.

02.

Delivery and retention directly at target tissue high in the nasal cavity, a feat not claimed by current liquid sprays in the market.

03.

Proprietary formulations (patentability).

# CANNABINOID SOL-GEL DELIVERY

WHY NOSE-TO-BRAIN?



01

### Direct Drug Delivery to Brain

Patient outcomes of cannabis based CNS drugs is hinged upon effective and sustained delivery to brain tissue



02

### Challenges with Oral Route


Rapid breakdown of enzymes in gut; incidences of GI distress on oral consumption of medical cannabis



03

### BBB Permeability

Difficult to reach the brain with drugs to treat neurological disorders due to blood-brain barrier



04

### Leverage Olfactory Pathway

Ideal pathway to deliver drugs directly to the brain via the Cannabinoid Sol-gel formulations

# CANNABINOID SOL-GEL DELIVERY

PreveCeutical® believes that the outcomes of its Cannabinoid Sol-gel Program may be of value to companies interested in delivering cannabinoid/cannabis-based-derived pharmaceuticals to the central nervous system (the “CNS”).

As medical research into the effects of cannabinoid acids in modulating disease pathways progresses and the expected benefits of cannabinoid acids emerge the company will be wellpositioned with its CBD Sol-Gel formulations.



“Sol-gel technology has certainly shown significant promise in laboratory testing at this point. Eventually, I would like to see this proprietary technology be successfully applied to a drug which could be targeted for CNS delivery. At the right time, we would welcome an opportunity to work with a pharmaceutical or biotechnology company to co-develop the Sol-gel and Sol-gel Applicator to be used in pharmaceutical and therapeutic products.”

**– President & Chief Science Officer,  
Dr. Mak Jawadekar.**

# BSV PEPTIDE PROGRAM

## TARGETING CANCER PROGRESSION

**Developing highly biostable peptides aiming to treat, regulate and prevent cancer progression.**

Peptides derived from the Blue Scorpion Venom ("BSV") have shown promise in delineating glioma tissue and preventing the invasion of gliomas through inhibition of extracellular matrix metalloprotease.

The re-designed and synthesized peptides were found to be equally or more potent in the cell-based activity assay when compared to another scorpion peptide, Chlorotoxin.

The peptides within scorpion venom are very complex molecules and challenging to manufacture. PreveCeutical's research team redesigned the peptides so they could be manufactured in the lab, addressing notable supply chain problems.

## NOTABLE

01.

Series of more comprehensive screening assays are underway in the final stages to develop a more detailed understanding of the activities of peptides in progressively complex cell-based brain cancer models.

02.

Filed a provisional application at the Australian Patent Office on Dec 2020, with the aim of seeking protection for certain cyclic peptides and their use in prevention and treatment of brain cancer.

# BSV PEPTIDE PROGRAM

## HOW THE LEAD PEPTIDES WERE IDENTIFIED?

Screening of the four peptides in an invasion assay model showed to have the ability to reduce the invasion potential in brain cancer cell types.

### 01.

#### Screening of 4 lead peptides

Identification of 4 lead peptides through preliminary screening in a glioblastoma cell-based assay.



### 02.

#### Disease Activity in Invasion Assay Model

Peptides derived from BSV have shown promise in delineating glioma tissue and preventing the invasion of gliomas through inhibition of extracellular matrix metalloprotease.



### 03.

#### In-vitro/ Cell-line Studies

Further evaluation in invitro studies in certain brain cancer cell lines and also in a patientderived neural oncosphere cell line of a brain cancer.

# BSV PEPTIDE PROGRAM

PreveCeutical® is now accelerating the process of evaluating options on how best to progress the two lead peptide drug candidates, which may include partnering to expedite their preclinical evaluation.

The pre-clinical outcomes, along with the Company's IP coverage, would have the potential to demonstrate proof of concept and enable the Company to further extend dialogue with pharma R & D / biotech companies active in the therapeutic neuro-oncology space.

The Peptide Program is expected to enable the company to develop their own proprietary, Nature Identical™, peptide therapeutics, which are intended for therapeutic applications.



"We are very excited with the results of the BSV program, and in particular with this lead peptide. Our plan is to utilize these results for a number of treatments, including management of GBM"

**– Chief Executive Officer,  
Mr. Stephen Van Deventer**

# PATENTS & LICENCING AGREEMENTS

## PATENT FAMILY TABLE

PATENT NAME	COUNTRY	FILING DATE	PUBLICATION DATE
PEPTIDES & USES THEREOF	INTERNATIONAL	2022.11.18	2023.05.25
CYCLIC PEPTIDES & USES THEREOF	INTERNATIONAL	2021.12.22	2022.06.30
CANNABINOID FORMULATIONS & METHODS OF USE	INTERNATIONAL	2021.08.31	2022.03.03
	AUSTRALIA	2023.02.28	
	EUROPE	2023.03.21	2023.07.05
	CANADA		2023.03.23
SOL-GEL CANNABINOID FORMULATION & ANTIVIRAL USE	INTERNATIONAL	2021.11.19	2022.05.27
	AUSTRALIA	2021.11.19	2022.05.27
	CANADA	2021.11.19	2022.05.27
PEPTIDES & USES THEREOF	INTERNATIONAL	2021.07.01	2022.01.06
	AUSTRALIA	2021.07.01	2022.01.06
	EUROPE	2021.07.01	2023.05.10
	CANADA	2021.07.01	2022.01.06
A CYCLIC PEPTIDE	INTERNATIONAL	2020.01.24	2020.07.30
	AUSTRALIA	2020.01.24	2020.07.30
	EUROPE	2020.01.24	2021.12.01
	CANADA	2020.01.24	2020.07.30
	USA	2020.01.24	2022.03.24

# PATENTS & LICENCING AGREEMENTS

## PATENT FAMILY TABLE

PATENT NAME	COUNTRY	FILING DATE	PUBLICATION DATE
DISULFIDE BOND CONTAINING  COMPOUNDS AND USES THEREOF	INTERNATIONAL	2018.07.26	2019.01.31
	AUSTRALIA	2022.12.15	2023.02.02
	EUROPE	2018.07.26	2020.06.03
	CANADA	2018.07.26	2019.01.31
	USA	2023.05.11	2023.05.11



# PREVECEUTICAL TEAM



**Stephen Van Deventer**  
– Chairman and Chief Executive Officer

Mr. Van Deventer is an experienced businessman and corporate director. Specializing in international corporate relations and business development over the last thirty-five years, Mr. Van Deventer has focused on launching small to medium-sized companies into the public markets in Canada, the United States, Europe and Australia. He has also owned and operated private companies.



**Mak Jawadekar PhD**  
– President, Chief Science Officer and Director

Dr. Jawadekar completed his Ph.D. in Pharmaceutics at the University of Minnesota. Dr. Jawadekar worked at Pfizer Inc. for twenty-eight years, where he most recently acted as the Director of Portfolio Management. During his career, he was responsible for drug delivery technology assessments involving external drug delivery technologies. Dr. Jawadekar has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies.

# PREVECEUTICAL TEAM



**Linnéa Olofsson PhD**  
– Director

Dr. Olofsson is an accomplished biophysicist with 12 years of laboratory research experience in academia, and 3 years working in the private sector as scientific support and equipment sales. She successfully advances science by providing counsel and training to the scientific community, contributing to executing strategic marketing plans by working in conjunction with the sales team members to identify and qualify sales leads through technical discussions. Dr. Olofsson closely collaborates with corporate strategic decision-making processes to penetrate new market applications to increase return on investment.



**Kathy Rokita CPA**  
– Director

Ms. Rokita is a finance, operations, and strategy-focused executive having extensive experience with large medical groups. Her involvement includes business development, information reporting, analytics, and improvements in financial performance and operational processes. She has a background in treasury management, budgeting, as well as mergers and acquisitions. Kathy has been appointed to PreveCeutical's audit committee. Kathy also selflessly dedicates time to volunteering as a board member for St. Vincent Hospital Foundation and Angelman Syndrome Foundation, where she served as Treasurer and President of the Board of Directors.

# PREVECEUTICAL TEAM



**C. Evan Ballantyne**  
– Director

Mr. Ballantyne has extensive executive leadership experience and has spent the last 20 years as a public and private company Chief Financial Officer in the healthcare industry. He was most recently the CFO of OncXerna Therapeutics Inc. where he worked to advance partnering opportunities for the company's biomarker program. Prior to OncXerna, Ballantyne was CFO at Orchestra BioMed Inc. where he assisted with the closing of two equity financing rounds with proceeds of \$57 million. At Orchestra, he also helped close a global partnership deal valued at more than \$200 million.



**Harry Parekh PhD, BSc Hons I**  
– Chief Research Officer

Based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE) in Australia, Dr. Parekh also holds an adjunct faculty position at Manipal University, India. Dr. Parekh heads the Drug/Gene Delivery Group at PACE-UQ with his team developing highly innovative and translational medicine delivery systems in-conjunction with physicians whose expertise span cancer, obesity-&-diabetes, macular disease, infectious disease, and neurological conditions.

# PREVECEUTICAL TEAM



**Louis Lapointe**  
– Director of Business Development

Mr. Lapointe is a business professional and investment banker with twenty-five years of experience across a myriad of business disciplines. He is French – English bilingual, in both the spoken and written word. Mr. Lapointe has board experience in private and publicly listed companies with extensive management and strategic planning experience. Oriented toward concrete results, Mr. Lapointe has a well-rounded knowledge of sales and marketing and national and international product placement.



**Sydney Cole**  
– Executive Assistant & Office Manager

Ms. Cole has held Administration Support and trainer roles within the Hospitality Industry for seven years. Ms. Cole has also worked for a Venture Capital company for seven years as an executive assistant and office manager. From bookkeeping to event coordination Ms. Cole's organization and fortitude keep operations running smoothly.

# PREVECEUTICAL AUSTRALIA TEAM

PreveCeutical® has established a wholly- owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests.

The Australian team, which will be led by Stephen Van Deventer, the Chief Executive Officer, will work closely with Dr. Harry Parekh, PreveCeutical's Chief Research Officer, to advance the company's therapeutic pipeline.

The office will also allow for better engagement with commercial partners on other ventures that PreveCeutical is pursuing in the region.



Stephen Van Deventer  
Chairman and Director

James Henderson  
Independent Director

# RESEARCH COLLABORATORS



**Murdoch**  
UNIVERSITY

Dr. Rakesh Veedu is leading the Precision Nucleic Acids Theranostics Group, as a McCusker Research Fellow with the Perron Institute for Neurological and Translational Science, based at the Centre for Comparative Genomics at Murdoch University (Perth, Australia). He is an emerging expert internationally in the field of molecular medicine, using nucleic acid-based biotechnologies and developing novel nucleic acid as potential drug therapies for a range of neurological diseases, genetic disorders and solid cancers.



**QIMR Berghofer**  
Medical Research Institute

Professor Grant Ramm is currently the head of the Hepatic Fibrosis Laboratory and Coordinator of the Cell and Molecular Biology Department at QIMR-Berghofer, a leading medical research institute located in Brisbane, Australia.

# RESEARCH COLLABORATORS

## Dr. Ajit Shetty

Dr. Shetty has extensive pharmaceutical experience leading commercial and supply chain operations as well as significant educational background including a PhD in Metallurgy from Trinity College at Cambridge University. Dr. Shetty spent 36 years at Johnson & Johnson (“J&J”) in a wide range of global roles. From 2007 to 2012, he served as Corporate Vice President, Enterprise Supply Chain reporting to the CEO and was responsible for the transformation and optimization of J&J’s supply chain. In addition, from 2004 to 2012, he served as chairman of Janssen Pharmaceutical.

## Aditya Bahl

Mr. Bahl brings over 20 years of experience in pharmaceutical marketing and clinical development and is known for his entrepreneurship and creativity. He is the CEO and founder of RAS LSS, a boutique healthcare consulting group based in Germany providing strategic guidance to biotechnology and pharmaceutical companies on franchise and product strategy, clinical development and commercialization.

# PARTNERS





# PLEASE CONTACT



Stephen Van Deventer  
[info@preveceutical.com](mailto:info@preveceutical.com)



Investor Relations  
[ir@preveceutical.com](mailto:ir@preveceutical.com)



1 (604) 416-7777